

ASX Announcement | 23 November 2020
Visioneering Technologies (ASX:VTI)

Visioneering launches education platform featuring leading eye care clinicians and researchers

Investment Highlights

- Visioneering has launched Shared Vision, an education platform to help eye care professionals worldwide easily understand issues related to myopia management in children and young adults
- Shared Vision features myopia insights from 15 global key opinion leaders in an easily consumable short video format
- Recent data showed in a real-world clinical setting that Visioneering's NaturalVue Multifocal lenses can slow or stop myopia progression in children

Atlanta, Georgia, Monday, 23 November 2020: US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses ('NaturalVue MF') **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering', 'VTI' or 'the Company') is pleased to announce the launch of Shared Vision, an education platform featuring some of the eye care industry's leading clinicians and researchers.

Nearsightedness, or "myopia", is affecting children at accelerating rates around the world, with 80-90% of children in many Asian countries suffering from myopia, double the rate of 30 years ago. Paediatric myopia typically worsens through childhood, adolescence, and early adulthood and correlates to elevated lifetime risk of serious ocular diseases, including blindness. Managing myopia as a progressive disease needing treatment beyond just vision correction is becoming an important aspect of eye care practices.

Shared Vision features insights on myopia management from 15 global key opinion leaders (KOLs) in an easily consumable short-video format. The aim of Shared Vision is to offer busy eye care professionals (ECPs) an easily consumed program that will help them understand myopia management and how to incorporate this important care into their practices.

Accelerating interest and rate of research

The understanding of myopia and how to manage it has greatly expanded in the past decade, with researchers, educators and clinicians studying, publishing and presenting new knowledge at an ever-accelerating pace. However, the amount of research and the expanding number of educational events held worldwide has made it increasingly difficult for ECPs to keep up with the latest in myopia management.

With many global educational events now paused due to the Covid-19 pandemic, Visioneering saw a unique opportunity to give ECPs anywhere in the world virtual access to KOLs willing to share their expertise with others. Shared Vision is a resource that brings information on myopia management to ECPs in a format that makes it easy for them to watch and learn when and where it is most convenient.

In the [Shared Vision section of Visioneering’s website](#) viewers can access a number of one to two-minute educational videos made by the KOLs on various aspects of myopia. Some of the topics include:

- Impact of Eye Growth Disease States (Professor Earl Smith, University of Houston, USA);
- Future Prevalence and Implications of Myopia (Professor Padmaja Sankaridurg, Brien Holden Vision Institute, Sydney, Australia);
- Contact Lenses and Safety with Children (Dr. Nicole Anstice, University of Canberra, Australia); and
- Multifocal Design and Myopia (Dr. Thomas Aller, San Francisco, CA, USA).

VTI is optimistic that ECPs worldwide will find Shared Vision to be an invaluable educational resource for their efforts to provide better myopia management for their patients. The content can be found at <https://global.vtvision.com/practitioner/education-resource>.

VTI is at the forefront of myopia management with its lenses being prescribed to children in 11 countries around the world. In data recently presented at the Global Myopia Symposium, practitioners showed in 153 children a durable and consistent ability of VTI’s NaturalVue Multifocal contact lenses to slow or stop the progression of myopia in children for as long as 5 years (see ASX release 27 September 2020).

Visioneering Technologies CEO Stephen Snowdy, PhD, said: “We are very excited to launch Shared Vision, an important educational initiative that we believe will greatly benefit ECPs worldwide. By partnering with 15 of the world’s top KOLs in the field of myopia, we have created easily consumable yet highly informative content which should prove very valuable to ECPs who struggle to stay abreast of the rapidly expanding knowledge and trends in myopia management. It is also worth noting that Shared Vision is not limited to ECPs and we encourage anyone whose life is impacted by myopia to visit the website and watch the videos.”

Ends

This release was authorized by the CEO, Stephen Snowdy, PhD.

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy, PhD CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Julia Maguire The Capital Network M: +61 419 815 386 E: julia@thecapitalnetwork.com.au

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering,

manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Canada, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

Foreign ownership restrictions

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX42